Biotech Values

[vinmantoo]

I think right now ENTA is bullish on RSV and wants to maximize that opportunity, and the timing is more optimal to partner covid before RSV data is in hand, so I would far prefer a royalty structure and let the partner fund the trials. ENTA could get creative and have an opt in clause, but that is normally done after phase 2 before phase 3 so doubt that is a reality. To have zero up front would suck either way and I don't think ENTA would accept anything less than a minimum up front that covers the investment in the program to date, and even that would be quite disappointing

Agree that there would have to be some upfront money to cover at least some of the EDP-235 development costs as well as costs for EDP-235 production for phase 3 trials.